source
- Pfizer reports positive Phase 3 results for Elrexfio in relapsed multiple myelomaPfizer announced that its antibody-drug conjugate Elrexfio achieved a statistically significant and clinically meaningful improvement in progression-free survival for patients with relapsed or refr…
- Chiesi to acquire KalVista for $1.9 billion, adding hereditary angioedema pill to rare-disease portfolioItalian pharmaceutical group Chiesi announced it will purchase KalVista Therapeutics for $1.9 billion. The transaction values KalVista at $27 per share, a 40 percent premium to its last closing pri…